Moleculin Biotech, Inc.
MBRX
Positions held
Your positionsMBRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $8.64M | Enterprise value | $1.29M | Trailing P/E | 0.05 | Forward P/E | -0.00 |
| PEG | — | Price / book | 0.26 | Beta | 2.00 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -13.7% | ROA | -84.6% | Debt / equity | 0.03 |
| Current ratio | 0.94 | Free cash flow | -$14.92M | Analyst recommendation | strong_buy | Mean target | $12.00 |
| 52w high | $15.75 | 52w low | $0.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$7.6M | -$12.8M | $15.6M | -$25.4M | -$17.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.6M | -$7.9M | -$7.5M | -$5.9M | -$5.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$33.6M | -$26.0M | -$29.8M | -$29.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$25.1M | -$26.6M | -$29.6M | -$30.6M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
2026-09-25 · Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
2026-09-23 · Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
2026-09-14 · Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
2026-09-11 · Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
2026-08-27 · Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
2026-08-24 · Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why
2026-07-31 · Moleculin Announces Pricing of $9.3 Million Public Offering
2026-07-31 · Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
2026-07-29 · Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall
Price (daily)
Full chart · RSI · MACD · patterns